OUR STRATEGY

We invest in transformative therapeutics companies addressing major unmet medical needs

Pathway Bioventures is a seed-stage life sciences fund investing in next-generation precision therapeutics companies. We support extraordinary teams leveraging cutting-edge biotechnology to address major unmet medical needs. Pathway co-invests in early financing rounds within high-quality syndicates.

Beyond our investment, we dedicate ourselves to helping entrepreneurs grow their companies, with specific focus on supporting the seed to Series A transition and development of capital-efficient derisking strategies. We are selective in our investments and build a deep understanding of the technology and its market value. Armed with this knowledge, we become a valuable extension of the early team as we help companies build relationships with future investors and partners, including top biotech VCs and pharma corporate venture arms.

Areas of interest

We focus on genetic medicine and targeted therapies for molecularly-defined patient populations. We believe in a future where such therapies are the standard of care. Specifically, we are interested in:  

· Gene therapy, cell therapy, oligonucleotide therapeutics

· RNA and DNA editing

· Disease driver-targeting small molecules, antibodies, antibody-drug conjugates

· Other targeted therapies for well-defined diseases